** U.S. shares of drug developer Atai Life Sciences 9VC.DE, ATAI.O rise 5.5% to $1.53 premarket

** Co, along with partner Beckley Psytech, reports results from mid-stage trial of its experimental treatment for alcohol use disorder

** Co says a single dose of the therapy, BPL-003, in combination with behavioral therapy shows sustained reduction in alcohol use and heavy drinking days up to 12 weeks

** The study enrolled 12 patients with the disorder - characterized by an impaired ability to stop or control alcohol use despite adverse health consequences

** BPL-003 was shown to be well-tolerated with no serious or severe adverse events reported

** Co anticipates reporting additional data from this study in publications and conferences later this year

** ATAI fell 5.6% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))